Cunning Capital Partners LP Makes New $1.11 Million Investment in Hims & Hers Health, Inc. $HIMS

Cunning Capital Partners LP purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 34,200 shares of the company’s stock, valued at approximately $1,110,000.

A number of other large investors also recently bought and sold shares of HIMS. Flagship Harbor Advisors LLC purchased a new position in Hims & Hers Health during the fourth quarter worth approximately $28,000. Binnacle Investments Inc acquired a new stake in shares of Hims & Hers Health in the third quarter worth $28,000. Bogart Wealth LLC increased its position in shares of Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after acquiring an additional 632 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health in the first quarter worth $30,000. Finally, Entrust Financial LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter worth $47,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Activity

In related news, COO Michael Chi sold 97,289 shares of the firm’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the sale, the chief operating officer directly owned 407,282 shares of the company’s stock, valued at approximately $10,055,792.58. This trade represents a 19.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Soleil Boughton sold 9,463 shares of the firm’s stock in a transaction on Monday, April 20th. The shares were sold at an average price of $30.00, for a total transaction of $283,890.00. Following the sale, the insider directly owned 299,368 shares of the company’s stock, valued at approximately $8,981,040. The trade was a 3.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 212,807 shares of company stock valued at $5,473,644 in the last 90 days. Company insiders own 11.76% of the company’s stock.

Hims & Hers Health Price Performance

HIMS opened at $29.02 on Wednesday. The company has a fifty day simple moving average of $24.93 and a 200 day simple moving average of $26.91. The firm has a market cap of $6.72 billion, a price-to-earnings ratio of -322.40, a PEG ratio of 50.98 and a beta of 2.37. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The firm had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. Hims & Hers Health’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.20 earnings per share. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on HIMS shares. Weiss Ratings lowered shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. BTIG Research reissued a “neutral” rating on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Citigroup increased their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. Finally, Evercore set a $24.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus target price of $28.70.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.